Wikipedia -WSS

Wikipedia

author：knowledge 2025-09-28 21:05:15 - browse：593

a doctor wraps a smart watch around a patient's wrist — Adobe

As pharma companies wrestle with how and when to use wearables and other digital technologies to measure how their experimental drugs impact patients, clinical research giant Icon has acquired HumanFirst, which helps companies answer exactly those sorts of questions.

Founded in 2017, HumanFirst maintains a meticulously organized library of digital measurement tools, their underlying evidence, and information about how they have been used in clinical trials. Called Atlas, the platform is designed so that a trial sponsor can research what tools are available to measure things like physical activity or sleep for many commonly studied diseases. CEO Andy Coravos said that robust intelligence can help developers move more quickly and avoid mistakes that require costly changes to trial protocols.

Following the acquisition, HumanFirst will be another offering for Icon, which earned $8 billion last year running clinical trials for pharmaceutical companies and other related services. As of 2021, HumanFirst had raised $15 million in venture capital funding, and the decision to sell to Icon for an undisclosed amount comes as some big drug companies are reevaluating their approach to digital technologies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

hotspot

WSS

Superbugs, antibiotic resistance get scrutiny in congress

Medicare proceeds with plan to claw back hospital funds

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Companies helping big Covid

Kidney transplant patients stopped immunosuppressants in trial

Readout LOUD podcast: ESMO highlights & Roivant's big deal

explore

Wikipedia

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Inflation cooled significantly in June, bringing price hikes close to normal levels

23andMe had bad news about my health. I wish a person had delivered it

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

At least 13 dead in Texas as scorching temps continue

Inflation cooled significantly in June, bringing price hikes close to normal levels

Duchenne breakthrough therapy leaves behind pioneering families

Brain injuries and the importance of a second opinion

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Kidney transplant patients stopped immunosuppressants in trial

focus

Women's World Cup brings attention to abuse in soccer

A Greenpeace activist is fined for crash

Explaining an after

After half a century, Israel moves to evict squatter from his cave home on the beach

Live blog: Hearing on CRISPR

Gene therapy’s promise and the high cost of hope

explore

hotspot

hotspot

leisure time